News Column

Data on Hemodialysis Described by Researchers at Department of Medicine (An Evaluation of Oral Dabigatran Etexilate Pharmacokinetics and...

August 20, 2014



Data on Hemodialysis Described by Researchers at Department of Medicine (An Evaluation of Oral Dabigatran Etexilate Pharmacokinetics and Pharmacodynamics in Hemodialysis)

By a News Reporter-Staff News Editor at Biotech Week -- Data detailed on Hemodialysis have been presented. According to news reporting out of Halifax, Canada, by NewsRx editors, research stated, "Dabigatran etexilate represents a possible improved alternative to warfarin for anticoagulation in hemodialysis patients with atrial fibrillation (AF). The objective was to determine dabigatran plasma concentrations and anticoagulant effects following administration of a single 110 mg oral dose of dabigatran etexilate to 10 adult patients immediately prior to starting hemodialysis."

Our news journalists obtained a quote from the research from the Department of Medicine, "Mass spectrometry and the Hemoclot assay were used, respectively, to determine free (unconjugated) dabigatran concentrations and thrombin time (TT) in plasma samples collected intermittently over 48 hours. The median time (t(max)) to reach the maximum plasma-free dabigatran concentration (C-max) was 2 hours (range 1-3 hours). The mean free dabigatran C-max was 95.5 +/- 33.4 ng/mL. The mean elimination half-lives on and off hemodialysis were, respectively, 2.6 +/- 1.3 and 30.2 +/- 7.8 hours. Hemodialysis effectively removed dabigatran with an extraction ratio of 0.63 +/- 0.07. The maximal TT ratio was 2.1 and the TT ratio demonstrated a strong linear dependence on free dabigatran concentration (r(2) = 0.741). A 110 mg oral dabigatran dose prior to hemodialysis was rapidly absorbed and achieved therapeutic concentrations."

According to the news editors, the research concluded: "Hemodialysis effectively removed dabigatran from the plasma and may be an effective means of accelerating the elimination of dabigatran in circumstances of excessive anticoagulation."

For more information on this research see: An Evaluation of Oral Dabigatran Etexilate Pharmacokinetics and Pharmacodynamics in Hemodialysis. Journal of Clinical Pharmacology, 2014;54(8):901-909. Journal of Clinical Pharmacology can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Sage Publications - www.sagepub.com/; Journal of Clinical Pharmacology - jcp.sagepub.com)

Our news journalists report that additional information may be obtained by contacting J.A.S. Wilson, Capital Dist Hlth Author, Dept. of Med, Div Hematol, Halifax, NS, Canada. Additional authors for this research include K.B. Goralski, S.D. Soroka, M. Morrison, P. Mossop, L. Sleno, Y. Wang and D.R. Anderson (see also Hemodialysis).

Keywords for this news article include: Pharmaceuticals, Drugs, Canada, Halifax, Therapy, Nova Scotia, Hemodialysis, Renal Dialysis, Pharmacokinetics, North and Central America

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters